Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy

Southern African Journal of HIV Medicine

 
 
Field Value
 
Title Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy
 
Creator Mulubwa, Mwila Viljoen, Michelle Kruger, Iolanthe M. Kruger, Herculina S. Rheeders, Malie
 
Subject Clinical Pharmacology Tenofovir levels; Bone turnover markers; Female HIV-infected
Description Background: Tenofovir disoproxil fumarate (TDF) antiretroviral therapy is associated with disruption of the bone turnover process.Objectives: The objective of this study was to determine the association between tenofovir (TFV) plasma concentration and various bone turnover markers and compare these markers in HIV-infected women and HIV-uninfected controls.Method: A cross-sectional sub-study included 30 HIV-infected women on TDF and 30 HIV-uninfected matched participants. Serum calcium (SrCa), serum phosphate (SrP), C-terminal telopeptide (CTx), parathyroid hormone (PTH), alkaline phosphatase (ALP), C-reactive protein (CRP), vitamin D (VitD) and bone mineral density (BMD) were measured. Plasma TFV was assayed on HPLC-MS/MS. The statistical tests applied were Mann–Whitney test, unpaired t-test, analysis of covariance, regression and correlation analysis.Results: In HIV-infected women, no correlation existed between plasma TFV concentration and CTx, PTH, ALP, SrCa, SrP, VitD or BMD (p 0.05). After adjusting for smoking and alcohol use, ALP (p 0.001), CTx (p = 0.027) and PTH (p = 0.050) were significantly higher in HIV-infected compared to HIV-uninfected women. Women with TFV concentration ≥ 120 ng/mL had higher PTH concentrations (p = 0.037) compared to those with ≤ 100 ng/mL. Significant correlations between SrCa and PTH and SrCa and SrP including CTx and PTH (p 0.05) were present in HIV-uninfected women while absent in HIV-infected counterparts (p 0.05).Conclusion: The results indicate possible increased bone turnover at higher TFV concentrations. The normal regular bone turnover processes in HIV-infected women on TDF therapy are altered. Larger studies are warranted to confirm these results.
 
Publisher AOSIS
 
Contributor Centre of Excellence for Pharmaceutical Sciences (Pharmacen), Division of Pharmacology, North–West University, Potchefstroom Campus
Date 2017-12-06
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Quantitative; Cross-sectional
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajhivmed.v18i1.739
 
Source Southern African Journal of HIV Medicine; Vol 18, No 1 (2017); 7 pages 2078-6751 1608-9693
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajhivmed.org.za/index.php/hivmed/article/view/739/1063 https://sajhivmed.org.za/index.php/hivmed/article/view/739/1062 https://sajhivmed.org.za/index.php/hivmed/article/view/739/1064 https://sajhivmed.org.za/index.php/hivmed/article/view/739/1054
 
Coverage — — Black HIV-infected women, mean (sd) age 53 (9.3) years.30 black uninfected women (60 (11) year). All with similar socio–demographic characteristics, mainly from the low-income group.
Rights Copyright (c) 2017 Mwila Mulubwa, Michelle Viljoen, Iolanthe M. Kruger, Herculina S. Kruger, Malie Rheeders https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT